Suppr超能文献

比较晚期肝门部胆管癌患者单独行胆道支架置入术与光动力疗法的长期疗效。

Longterm outcome of photodynamic therapy compared with biliary stenting alone in patients with advanced hilar cholangiocarcinoma.

机构信息

Department of Internal Medicine, Digestive Disease Centre, Konkuk University School of Medicine, Seoul, South Korea.

出版信息

HPB (Oxford). 2012 Mar;14(3):185-93. doi: 10.1111/j.1477-2574.2011.00424.x. Epub 2012 Jan 6.

Abstract

OBJECTIVES

This study aimed to determine longterm outcomes and factors associated with increased survival after photodynamic therapy (PDT) compared with endoscopic biliary drainage alone in patients presenting with advanced hilar cholangiocarcinoma (CC).

METHODS

A retrospective analysis of the institutional database identifying all patients who presented with a diagnosis of hilar CC between December 1999 and January 2011 was conducted.

RESULTS

Of the 232 patients identified, 72 (31%) were treated with PDT (Group A) and 71 (31%) were treated with endoscopic biliary drainage alone (Group B). Median survival was 9.8 months [95% confidence interval (CI) 7.42-12.25] in Group A and 7.3 months (95% CI 4.79-9.88) in Group B (P= 0.029). On multivariate analysis, biliary drainage without PDT (P= 0.025) and higher T-stage (P= 0.002) were significant predictors of shorter survival in all patients. In a subgroup analysis of patients in the PDT group, lower pre-PDT bilirubin level (P= 0.005), multiple PDT treatments (P= 0.044) and shortened time to treatment after diagnosis (P= 0.013) were significant predictors of improved survival. Median metal stent patency was longer in Group A than in Group B (215 days vs. 181 days; P= 0.018).

CONCLUSIONS

Photodynamic therapy with stenting resulted in longer survival than stenting alone. Early PDT after diagnosis and multiple PDT treatments were shown to have survival benefits. Metal stent patency was longer in patients receiving PDT. Higher T-stage appears to be a predictor of early mortality in advanced bile duct cancer treated with PDT.

摘要

目的

本研究旨在比较 PDT 与单纯内镜胆道引流治疗晚期肝门部胆管癌(CC)患者的长期疗效及生存率的影响因素。

方法

回顾性分析了 1999 年 12 月至 2011 年 1 月期间确诊为肝门部 CC 的所有患者的机构数据库。

结果

在 232 例患者中,72 例(31%)接受 PDT(A 组)治疗,71 例(31%)接受单纯内镜胆道引流治疗(B 组)。A 组中位生存时间为 9.8 个月(95%CI:7.42-12.25),B 组为 7.3 个月(95%CI:4.79-9.88)(P=0.029)。多因素分析显示,未行 PDT 的胆道引流(P=0.025)和更高的 T 分期(P=0.002)是所有患者生存时间较短的显著预测因素。在 PDT 组患者的亚组分析中,较低的 PDT 前胆红素水平(P=0.005)、多次 PDT 治疗(P=0.044)和诊断后治疗时间缩短(P=0.013)是生存时间改善的显著预测因素。A 组金属支架通畅时间长于 B 组(215 天 vs. 181 天;P=0.018)。

结论

支架置入联合 PDT 治疗比单纯支架置入的生存时间更长。早期诊断后进行 PDT 治疗和多次 PDT 治疗具有生存获益。接受 PDT 治疗的患者金属支架通畅时间更长。T 分期较高似乎是 PDT 治疗晚期胆管癌早期死亡的预测因素。

相似文献

1
Longterm outcome of photodynamic therapy compared with biliary stenting alone in patients with advanced hilar cholangiocarcinoma.
HPB (Oxford). 2012 Mar;14(3):185-93. doi: 10.1111/j.1477-2574.2011.00424.x. Epub 2012 Jan 6.
2
Photodynamic therapy prolongs metal stent patency in patients with unresectable hilar cholangiocarcinoma.
World J Gastroenterol. 2012 Oct 21;18(39):5589-94. doi: 10.3748/wjg.v18.i39.5589.
6
Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy.
Clin Gastroenterol Hepatol. 2008 Mar;6(3):290-7. doi: 10.1016/j.cgh.2007.12.004. Epub 2008 Feb 6.
8
Biliary drainage, photodynamic therapy and chemotherapy for unresectable cholangiocarcinoma with jaundice.
J Gastroenterol Hepatol. 2009 Nov;24(11):1745-52. doi: 10.1111/j.1440-1746.2009.05915.x. Epub 2009 Sep 25.
10
R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer.
Liver Int. 2011 Jan;31(1):99-107. doi: 10.1111/j.1478-3231.2010.02345.x. Epub 2010 Sep 16.

引用本文的文献

1
Advances in Endoscopic Diagnosis and Management of Cholangiocarcinoma.
J Clin Med. 2025 Aug 26;14(17):6028. doi: 10.3390/jcm14176028.
3
Promising Highly Targeted Therapies for Cholangiocarcinoma: A Review and Future Perspectives.
Cancers (Basel). 2023 Jul 20;15(14):3686. doi: 10.3390/cancers15143686.
4
Role of radiofrequency ablation in advanced malignant hilar biliary obstruction.
Clin Endosc. 2023 Mar;56(2):155-163. doi: 10.5946/ce.2022.218. Epub 2023 Jan 16.
6
Comparing palliative treatment options for cholangiocarcinoma: photodynamic therapy vs. radiofrequency ablation.
Clin Endosc. 2022 May;55(3):347-354. doi: 10.5946/ce.2021.274. Epub 2022 May 17.
7
Endoscopic Management of Pancreatobiliary Malignancies.
Dig Dis Sci. 2022 May;67(5):1635-1648. doi: 10.1007/s10620-022-07394-y. Epub 2022 Feb 16.
8
Ablative therapies of the biliary tree.
Transl Gastroenterol Hepatol. 2021 Oct 25;6:63. doi: 10.21037/tgh.2020.02.03. eCollection 2021.
9
Ablative therapies for hepatic and biliary tumors: endohepatology coming of age.
Transl Gastroenterol Hepatol. 2020 Apr 5;5:15. doi: 10.21037/tgh.2019.10.17. eCollection 2020.
10
Endoscopic Palliation for Biliary and Pancreatic Malignancies: Recent Advances.
Clin Endosc. 2019 May;52(3):226-234. doi: 10.5946/ce.2019.003. Epub 2019 Jan 22.

本文引用的文献

2
Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy.
Am J Gastroenterol. 2007 Oct;102(10):2164-70. doi: 10.1111/j.1572-0241.2007.01403.x. Epub 2007 Jul 7.
3
Factors associated with increased survival after photodynamic therapy for cholangiocarcinoma.
Clin Gastroenterol Hepatol. 2007 Jun;5(6):743-8. doi: 10.1016/j.cgh.2007.02.021.
4
Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.
Br J Cancer. 2007 Mar 26;96(6):896-902. doi: 10.1038/sj.bjc.6603648. Epub 2007 Feb 27.
5
Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy.
Am J Gastroenterol. 2005 Nov;100(11):2426-30. doi: 10.1111/j.1572-0241.2005.00318.x.
8
Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study.
Gastroenterology. 2003 Nov;125(5):1355-63. doi: 10.1016/j.gastro.2003.07.015.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验